Hybrid Organ GmbH
is a Berlin-based biomed company engaged in the development and commercialization
of advanced cell culture bioreactors. The company´s patented core
technologies serve as a platform for a wide range of potential products
in numerous medical markets. They address both clinical needs in the field
of cell based therapies, and research needs in stem cell technology for
hybrid organ development. Our primary focus is on liver therapy.
We all hope to enjoy a long and healthy life. Despite great advances in
medicine, liver disease remains the fourth leading cause of death. Hybrid
Organ, one of the leading companies in medical bioreactor development,
continues to make a substantial contribution to the treatment of liver
disease. Our first commercial product is the Modular Extracorporeal Liver
System - MELS - for clinical therapy in liver intensive care units. The
MELS serves as an innovative platform for liver support technology. It
enables temporary extracorporeal support of patients in severe liver failure.
A modular concept allows treatment with different levels of complexity
for relevant indications of liver injury. The most complex module enables
the utilization of liver cells in bioreactor culture. This hybrid liver
module performs synthesis, metabolism and regulation of the failing organ.
The system has already undergone initial testing in therapy, and is currently
the focus of clinical studies.